BioPorto A/S
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Carsten Buhl
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Tuborg Havnevej 15, st. Hellerup CR Denmark 2900
- IPO Date
- Jan 2, 1985
- Website
- bioporto.com
- Similar Companies
- Business
- BioPorto A/S is an in vitro diagnostics company specializing in the development and commercialization of biomarker-based tests, primarily focusing on the NGAL (Neutrophil Gelatinase-Associated Lipocalin) biomarker for the risk assessment and diagnosis of Acute Kidney Injury (AKI). The company’s core products include NGAL-based diagnostic assays such as enzyme-linked immunosorbent assay (ELISA) kits, automated in vitro diagnostic tests, and the ProNephro AKI™ test designed for early detection of AKI in clinical settings. These products aim to improve patient management by enabling earlier intervention and more precise risk stratification compared to traditional diagnostic methods. BioPorto also leverages its proprietary assay development platform and antibody expertise to create a pipeline of novel diagnostic tests targeting conditions with significant unmet medical needs. The company operates globally with significant commercial presence and growth in the US and Europe and holds CE marks for several products enabling broad distribution. Founded in 2000 and headquartered in Hellerup, Denmark, BioPorto recently appointed Carsten Buhl as CEO effective September 2025 as part of a strategic leadership transition. In 2024 and 2025, the company achieved notable revenue growth, with a 17% increase overall and a 34% surge in US NGAL product sales, driven by expanded commercial activities including the hiring of sales and medical liaison staff in the US. BioPorto entered a major partnership with Beckman Coulter to enhance its commercial reach and signed new instrument partnerships, notably with Roche for the commercial launch of ProNephro AKI on Roche’s automated analyzers. The company made progress in clinical trials aiming for FDA approval of ProNephro AKI for adult use in the US market, targeting a significant market opportunity estimated at USD 2.8 billion. Additionally, BioPorto completed multiple capital raises, including a DKK 43 million equity issuance in late 2025, to fund clinical development and commercialization initiatives. The company continues to expand its presence in global markets while advancing regulatory approvals and commercial deployment of its NGAL diagnostic products.
Company News
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
Reminder: Register Now | Unlocking the Growth - BioPorto Investor Meeting, October 7
First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.
BioPorto annoncerer det midlertidige resultat for første kvartal af 2026
BioPorto announces Interim Result for the First Quarter of 2026
BioPorto A/S afholder webcast for investorer om resultatet for første kvartal 2026
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
KDIGO offentliggør udkast til klinisk praksis guideline 2026 for akut nyreskade og akut nyresygdom
KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease
BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering